英文摘要 |
Over the past decades, there has been an increase in the use of novel treatment options such as targeted therapy, immunotherapy and biologics, particularly in oncology practice. Although these agents are thought to be more specific and less toxic than traditional cytotoxic chemotherapy, they are associated with a variety of toxicities, including ocular side effects due to their specific targeting activities in the eye. In this article, we discussed the proposed pathogenesis, monitoring guidelines, and management recommendations for the adverse events of these agents on external eye. Collaboration between oncologists and ophthalmologists is essential to diagnose and treat these side effects promptly. |